Boehringer Ingelheim Animal Health (BI) announced the recipients of the 2021 Awards for Advancing Equine Research at the American Association of Equine Practitioners Annual Convention in Nashville, Tennessee. The recipients were chosen based on their research proposals focused on equine infectious respiratory diseases and equine asthma syndrome.
The recipients are:
- Mathilde Leclere, DVM, PhD, DACVIM and Berta Mozo, DVM (resident), University of Montreal, St-Hyacinthe, Quebec, Canada
- Angela Bordin, Med Vet, MS, PhD and Bibiana Petri da Silveira, MS (graduate student), Texas A&M University, College Station, Texas
- Nicola Pusterla, DVM, PhD, DACVIM, DAVDC, University of California Davis, Davis, California
- Kelsey Hart, DVM, PhD, DACVIM and Londa J. Berghaus, MS (graduate student), University of Georgia, Athens, GA
Each recipient will receive a minimum of $ 15,000 in support of their research.
Since 2011, Boehringer Ingelheim has contributed nearly $ 700,000 to advance knowledge about equine disease, including the $ 75,000 in grants awarded this year.
“Boehringer Ingelheim is committed to championing the health and welfare of horses, and as a global leader in equine health, we are committed to helping advance equine health care to the highest possible level,” said said Steve Grubbs, DVM, PhD, DACVIM, equine technical manager for BI. “We have seen previous recipients make great strides in the area of asthma and equine respiratory disease and we are confident that the work of this year’s recipients will be equally revolutionary. “
Public and private veterinarians, diagnosticians, and researchers from the United States, Canada, and Mexico were eligible to submit proposals.
For more information on scholarships for the advancement of equine research, visit this page.
Boehringer Ingelheim Animal Health
The lives of animals and humans are interconnected in deep and complex ways. We know that when animals are healthy, humans are healthier too. Around the world, our 9,700 employees are dedicated to creating value through innovation, improving the well-being of both.
Respect for animals, humans and the environment guides us on a daily basis. We develop solutions and provide services to protect animals from disease and pain. We help our customers take care of the health of their animals and protect our communities from deadly and fatal diseases.
Boehringer Ingelheim Animal Health is the second largest animal health company in the world, with net sales of $ 4.7 billion (€ 4.1 billion) in 2020 and a presence in more than 150 countries.
Boehringer Ingelheim Animal Health has a significant presence in the United States, with more than 3,100 employees in locations that include Georgia, Missouri, Iowa, Minnesota, New Jersey, and Puerto Rico. To learn more, visit www.boehringer-ingelheim.us, www.facebook.com/BoehringerAHUS or www.twitter.com/Boehringer_AH.
Making new and better medicines for humans and animals is at the heart of what we do. Our mission is to create revolutionary therapies that change lives. Since its founding in 1885, Boehringer Ingelheim has been an independent, family-run business. We have the freedom to pursue our long-term vision, looking ahead to identify future health challenges and targeting areas of need where we can do the most good.
As a leading research-driven pharmaceutical company with approximately 52,000 employees, we create value daily through innovation in our three business areas: human pharmacy, animal health and manufacturing under biopharmaceutical contract.
In 2020, Boehringer Ingelheim achieved net sales of approximately $ 22.33 billion (€ 19.57 billion). Our significant investment of over $ 4.2 billion (€ 3.7 billion) in 2020 (18.9% of net sales) in R&D drives innovation, enabling the next generation of life-saving drugs and improve the quality of life.
We realize more scientific opportunities by leveraging the power of partnership and the diversity of experts in the life science community. By working together, we are accelerating the realization of the next medical breakthrough that will transform the lives of patients today and for generations to come.